Need help finding what you are looking for?
Contact Us
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1424107
PUBLISHER: Polaris Market Research | PRODUCT CODE: 1424107
Multiple Sclerosis Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Immunosuppressants, Immunomodulators); By Route of Administration; By Region; Segment Forecast, 2024 - 2032
PUBLISHED:
PAGES: 119 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global multiple sclerosis market size is expected to reach USD 33.57 billion by 2032, according to a new study by Polaris Market Research. The report "Multiple Sclerosis Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Immunosuppressants, Immunomodulators); By Route of Administration; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.
The increased emphasis on research and development (R&D) for the creation of ground-breaking pharmaceuticals by prominent industry participants is credited with the global market's expansion. For instance, Adamas Pharmaceuticals Inc. announced findings from a phase 3 clinical trial evaluating ADS-5102, an investigational amantadine agent designed to treat patients with multiple sclerosis (MS), in December 2020.
Product introductions, escalating governmental efforts to improve treatment and care accessibility, and the rising incidence of multiple sclerosis are anticipated to drive market growth.
The growing global impact of multiple sclerosis is causing increasing concern among healthcare providers and governments. The disease's rising prevalence has compelled governments in a number of countries to take proactive measures, such as developing guidelines and recommendations.
Also, government organizations are launching a variety of awareness campaigns to educate patients about the various treatment options which are available.
For instance, the German Multiple Sclerosis Society runs three to four industries in Germany to help people with Multiple Sclerosis. They organize a World MS Day competition every May 31st with the goal of removing accessibility barriers and extending the support network for those affected by multiple sclerosis.
Monoclonal antibodies are becoming more popular in the treatment of multiple sclerosis. Many companies are committed to developing new drugs for multiple sclerosis by leveraging the potential of these antibodies. Furthermore, global demand for humanized monoclonal antibodies, a common class of immunosuppressive drugs used to treat multiple sclerosis, is increasing. Particularly, Ocrevus, introduced by F. Hoffmann-La Roche Ltd., has emerged as the biggest drug, contributing to a substantial revenue and contributing to the market's continuous growth.
Multiple Sclerosis Market Report Highlights
The immunomodulators segment held the largest revenue share in the multiple sclerosis market. The expansion of immunomodulator treatment options and the introduction of new products for treating the disease is contribute to the growth of the market.
The oral segment is witnessed for the fastest market growth during the forecast period. owing to the launch of new products and the incline towards the oral drugs are the key factors which bolster the growth of the segment.
North America accounted for the largest market share. The north america is the most important market for companies such as Biogen, Novartis AG, and Sanofi SA. As a result, these companies are prioritizing the introduction of their most recent pharmaceuticals in market.
The Asia-Pacific region witnessed for the fastest growth in the multiple sclerosis market, the substantial growth rate is ascribed to the enhanced distribution networks of an pharmaceutical companies in the region. The growing implementation of government initiatives in a number of countries aimed at lowering the costs associated with MS treatment is a key driver driving the region's demand for MS drugs.
The global key market players include Hoffmann-La Roche Ltd., Bayer Healthcare AG, Teva Pharmaceuticals, GlaxoSmithKline, AbbVie, Inc., Sonafi Pasteur, Pfizer Inc., Merck & Company, Novartis AG, AB Science, and Opexa.
Polaris Market Research has segmented the multiple sclerosis market report based on drug type, route of administration and region:
Multiple Sclerosis, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)
- Immunosuppressants
- Lemtarda
- Ocrelizumab
- Zinbryta
- Aubagio
- Immunomodulators
- Ampyra
- Capxone
- Betaseron/Extavia
- Gilneya
- Avonex/Plegridy
- Tyasabri
- Rebif
- Teucifidera
Multiple Sclerosis, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)
- Injectable Agents
- Oral Agents
Multiple Sclerosis, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Product Code: PM1343
Table of Contents
1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
2. Executive Summary
- 2.1. Market Highlights
3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
4. Global Multiple Sclerosis Market Insights
- 4.1. Multiple Sclerosis Market - Industry Snapshot
- 4.2. Multiple Sclerosis Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Rise in the number of FDA approval will drive the growth of the market
- 4.2.1.2. Surge in the investment for healthcare infrastructure will bolster the growth of the market
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High cost associated with the drugs hindering the growth of the market
- 4.2.1. Drivers and Opportunities
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTLE Analysis
- 4.5. Multiple Sclerosis Industry trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
5. Global Multiple Sclerosis Market, by Drug type
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. Global Multiple Sclerosis, by Drug type, 2019-2032 (USD Billion)
- 5.3. Immunosuppressants
- 5.3.1. Global Multiple Sclerosis Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
- 5.3.2. Lemtarda
- 5.3.2.1. Global Multiple Sclerosis Market, by Lemtarda, by Region, 2019-2032 (USD Billion)
- 5.3.3. Ocrelizumab
- 5.3.3.1. Global Multiple Sclerosis Market, by Ocrelizumab, by Region, 2019-2032 (USD Billion)
- 5.3.4. Zinbryta
- 5.3.4.1. Global Multiple Sclerosis Market, by Zinbryta, by Region, 2019-2032 (USD Billion)
- 5.3.5. Aubagio
- 5.3.5.1. Global Multiple Sclerosis Market, by Aubagio, by Region, 2019-2032 (USD Billion)
- 5.4. Immunosuppressants
- 5.4.1. Global Multiple Sclerosis Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
- 5.4.2 Ampyra
- 5.4.21. Global Multiple Sclerosis Market, by Ampyra, by Region, 2019-2032 (USD Billion)
- 5.4.3 Capxone
- 5.4.3.1. Global Multiple Sclerosis Market, by Capxone, by Region, 2019-2032 (USD Billion)
- 5.4.4 Betaseron/Extavia
- 5.4.4.1. Global Multiple Sclerosis Market, by Betaseron/Extavia, by Region, 2019-2032 (USD Billion)
- 5.4.5 Gilneya
- 5.4.5.1. Global Multiple Sclerosis Market, by Gilneya, by Region, 2019-2032 (USD Billion)
- 5.4.6 Avonex/Plegridy
- 5.4.6.1. Global Multiple Sclerosis Market, by Avonex/Plegridy, by Region, 2019-2032 (USD Billion)
- 5.4.7 Tyasabri
- 5.4.7.1. Global Multiple Sclerosis Market, by Tyasabri, by Region, 2019-2032 (USD Billion)
- 5.4.8 Rebif
- 5.4.8.1. Global Multiple Sclerosis Market, by Rebif, by Region, 2019-2032 (USD Billion)
- 5.4.9 Teucifidera
- 5.4.91. Global Multiple Sclerosis Market, by Teucifidera, by Region, 2019-2032 (USD Billion)
6. Global Multiple Sclerosis Market, by Route of Administration
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 6.3. Injectable Agents
- 6.3.1. Global Multiple Sclerosis Market, by Injectable Agents, by Region, 2019-2032 (USD Billion)
- 6.4. Oral Agents
- 6.4.1. Global Multiple Sclerosis Market, by Oral Agents, by Region, 2019-2032 (USD Billion)
7. Global Multiple Sclerosis Market, by Geography
- 7.1. Key findings
- 7.2. Introduction
- 7.2.1. Multiple Sclerosis Market Assessment, By Geography, 2019-2032 (USD Billion)
- 7.3. Multiple Sclerosis Market - North America
- 7.3.1. North America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.3.2. North America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.3.3. Multiple Sclerosis Market - U.S.
- 7.3.3.1. U.S.: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.3.3.2. U.S.: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.3.4. Multiple Sclerosis Market - Canada
- 7.3.4.1. Canada: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.3.4.2. Canada: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.4. Multiple Sclerosis Market - Europe
- 7.4.1. Europe: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.4.2. Europe: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.4.3. Multiple Sclerosis Market - UK
- 7.4.3.1. UK: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.4.3.2. UK: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.4.4. Multiple Sclerosis Market - France
- 7.4.4.1. France: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.4.4.2. France: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.4.5. Multiple Sclerosis Market - Germany
- 7.4.5.1. Germany: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.4.5.2. Germany: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.4.6. Multiple Sclerosis Market - Italy
- 7.4.6.1. Italy: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.4.6.2. Italy: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.4.7. Multiple Sclerosis Market - Spain
- 7.4.7.1. Spain: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.4.7.2. Spain: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.4.8. Multiple Sclerosis Market - Netherlands
- 7.4.8.1. Netherlands: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.4.8.2. Netherlands: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.4.9. Multiple Sclerosis Market - Russia
- 7.4.9.1. Russia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.4.9.2. Russia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.5. Multiple Sclerosis Market - Asia Pacific
- 7.5.1. Asia Pacific: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.5.2. Asia Pacific: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.5.3. Multiple Sclerosis Market - China
- 7.5.3.1. China: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.5.3.2. China: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.5.4. Multiple Sclerosis Market - India
- 7.5.4.1. India: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.5.4.2. India: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.5.5. Multiple Sclerosis Market - Malaysia
- 7.5.5.1. Malaysia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.5.5.2. Malaysia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.5.6. Multiple Sclerosis Market - Japan
- 7.5.6.1. Japan: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.5.6.2. Japan: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.5.7. Multiple Sclerosis Market - Indonesia
- 7.5.7.1. Indonesia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.5.7.2. Indonesia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.5.8. Multiple Sclerosis Market - South Korea
- 7.5.8.1. South Korea: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.5.8.2. South Korea: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.6. Multiple Sclerosis Market - Middle East & Africa
- 7.6.1. Middle East & Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.6.2. Middle East & Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.6.3. Multiple Sclerosis Market - Saudi Arabia
- 7.6.3.1. Saudi Arabia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.6.3.2. Saudi Arabia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.6.4. Multiple Sclerosis Market - UAE
- 7.6.4.1. UAE: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.6.4.2. UAE: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.6.5. Multiple Sclerosis Market - Israel
- 7.6.5.1. Israel: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.6.5.2. Israel: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.6.6. Multiple Sclerosis Market - South Africa
- 7.6.6.1. South Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.6.6.2. South Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.7. Multiple Sclerosis Market - Latin America
- 7.7.1. Latin America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.7.2. Latin America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.7.3. Multiple Sclerosis Market - Mexico
- 7.7.3.1. Mexico: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.7.3.2. Mexico: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.7.4. Multiple Sclerosis Market - Brazil
- 7.7.4.1. Brazil: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.7.4.2. Brazil: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- 7.7.5. Multiple Sclerosis Market - Argentina
- 7.7.5.1. Argentina: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- 7.7.5.2. Argentina: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
8. Competitive Landscape
- 8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
- 8.2. Partnerships/Collaborations/Agreements/Exhibitions
9. Company Profiles
- 9.1. Hoffmann-La Roche Ltd.
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
- 9.2. Bayer Healthcare AG
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
- 9.3. Teva Pharmaceuticals
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
- 9.4. GlaxoSmithKline
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
- 9.5. AbbVie Inc.
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
- 9.6. Sonafi Pasteur
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
- 9.7. Pfizer Inc
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
- 9.8. Merck & Company
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
- 9.9. Novartis AG
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
- 9.10. AB Science
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development
- 9.11. Opexa
- 9.11.1. Company Overview
- 9.11.2. Financial Performance
- 9.11.3. Product Benchmarking
- 9.11.4. Recent Development
Product Code: PM1343
List of Tables
- Table 1 Global Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 2 Global Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 3 Multiple Sclerosis Market Assessment, By Geography, 2019-2032 (USD Billion)
- Table 4 North America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 5 North America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 6 U.S.: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 7 U.S.: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 8 Canada: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 9 Canada: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 10 Europe: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 11 Europe: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 12 UK: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 13 UK: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 14 France: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 15 France: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 16 Germany: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 17 Germany: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 18 Italy: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 19 Italy: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 20 Spain: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 21 Spain: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 22 Netherlands: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 23 Netherlands: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 24 Russia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 25 Russia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 26 Asia Pacific: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 27 Asia Pacific: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 28 China: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 29 China: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 30 India: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 31 India: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 32 Malaysia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 33 Malaysia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 34 Japan: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 35 Japan: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 36 Indonesia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 37 Indonesia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 38 South Korea: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 39 South Korea: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 40 Middle East & Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 41 Middle East & Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 42 Saudi Arabia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 43 Saudi Arabia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 44 UAE: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 45 UAE: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 46 Israel: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 47 Israel: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 48 South Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 49 South Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 50 Latin America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 51 Latin America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 52 Mexico: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 53 Mexico: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 54 Brazil: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 55 Brazil: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
- Table 56 Argentina: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
- Table 57 Argentina: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
List of Figures
- Figure 1 Global Multiple Sclerosis Market, 2019-2032 (USD Billion)
- Figure 2 Integrated Ecosystem
- Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
- Figure 4 Market by Geography
- Figure 5 Porter's Five Forces
- Figure 6 Market by Route of Administration
- Figure 7 Global Multiple Sclerosis Market, by Route of Administration, 2022 & 2032 (USD Billion)
- Figure 8 Market by Drug type
- Figure 9 Global Multiple Sclerosis Market, by Drug type, 2022 & 2032 (USD Billion)
- Figure 10 Multiple Sclerosis Market Assessment, By Geography, 2019-2032 (USD Billion)
- Figure 11 Strategic Analysis - Multiple Sclerosis Market
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.